News & Updates
Showing Pharmacy articles
Showing
Show Multimedia Only

MAGNITUDE updates in Asian cohort boost NIRA-AAP benefit in BRCA+ mCRPC
13 Dec 2023
byAudrey Abella
In the second interim analysis of the Asian cohort from the phase III MAGNITUDE study, a combination regimen comprising niraparib and abiraterone acetate plus prednisone (NIRA-AAP) improved clinical outcomes in patients with BRCA+ metastatic castration-resistant prostate cancer (mCRPC).
13 Dec 2023

BPaLM regimen continues to show benefit against rifampicin-resistant tuberculosis
12 Dec 2023
byJairia Dela Cruz
In the treatment of patients with rifampicin-resistant tuberculosis, a 6-month oral regimen consisting of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) is safe and efficacious and compares favourably with standard of care, as shown in the final data from the phase IIB-III TB-PRACTECAL study.
12 Dec 2023







